Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical is supported by a dominant, well-entrenched robotic surgery ecosystem that has placed more than 11,000 da Vinci systems worldwide and generated over +20MM procedures, underscoring deep clinical adoption and high barriers to entry. Its 3Q26 results reinforce the thesis, with revenue of $3.049B, adjusted EPS of $3.00, 546 da Vinci placements, and stable U.S. procedure growth near 10% despite near-term I&A headwinds from extended-use pricing actions. The outlook remains constructive because the new DV5 cycle, rising ASC and international demand, expanding Force Feedback and SP adoption, and a global installed base of 12,094 systems should support durable volume, utilization, and margin resilience.

Intuitive Surgical is facing a less compelling near-term growth profile as U.S. da Vinci procedure growth decelerated to 10% in Q3 from 12% in Q2 and 14% in Q1, while management only narrowed FY26 procedure guidance to 14%-15% rather than raising it outright, leaving ambiguity around whether volumes have stabilized. China adds another layer of pressure, with the market described as challenging and a policy-driven charge code change set to drag on China I&A per-procedure revenue beginning in November 2026, while China already represents only about 5%-6% of global DV procedures and runs roughly 20% below the global blended average. Although margins remain strong with FY26 gross margin guidance of 68.7%-69.3% and dV5 adoption is improving, the combination of slower U.S. utilization, China pricing headwinds, and capital-spending and competitive risks suggests earnings momentum could soften before volume offsets materialize.